Pondel M - Search Results

1

P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.

Sands B, Pondel M, Silver M, Petersen A, Wolf D, Panaccione R, Loftus E Jr, Colombel JF, Sturm A, D'Haens G. Sands B, et al. Among authors: pondel m. Am J Gastroenterol. 2021 Dec 1;116(Suppl 1):S8. doi: 10.14309/01.ajg.0000798724.11932.76. Am J Gastroenterol. 2021. PMID: 37461950

2

[No title available]

[No authors listed] [No authors listed] PMID: 34848618

3

[No title available]

[No authors listed] [No authors listed] PMID: 35006159

4

[No title available]

[No authors listed] [No authors listed] PMID: 35006163

5

P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.

Hudesman D, Long M, Wolf D, Hanauer S, Ghosh S, Petersen A, Pondel M, Silver M, Cross R, Feagan B. Hudesman D, et al. Among authors: pondel m. Am J Gastroenterol. 2021 Dec 1;116(Suppl 1):S9. doi: 10.14309/01.ajg.0000798740.67469.6e. Am J Gastroenterol. 2021. PMID: 37461954

6

[No title available]

[No authors listed] [No authors listed] PMID: 35006166

7

P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.

Long M, Cross R, Calkwood J, Pondel M, Pai A, Ahmad H, Charles L, Elegbe A, Petersen A, Sheffield J, Javed A, Wolf D. Long M, et al. Among authors: pondel m. Am J Gastroenterol. 2021 Dec 1;116(Suppl 1):S9-S10. doi: 10.14309/01.ajg.0000798752.72296.f3. Am J Gastroenterol. 2021. PMID: 37461957

8

Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.

Abraham I, Calamia M, Alkhatib N, Pondel M, MacDonald K. Abraham I, et al. Among authors: pondel m. J Med Econ. 2024;27(sup3):36-50. doi: 10.1080/13696998.2024.2411877. Epub 2024 Oct 21. J Med Econ. 2024. PMID: 39359042 Free article.

9

Cost-efficiency and budget-neutral expanded access modeling of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.

MacDonald K, Pondel M, Abraham I. MacDonald K, et al. Among authors: pondel m. J Med Econ. 2024;27(sup3):24-33. doi: 10.1080/13696998.2024.2380872. Epub 2024 Aug 1. J Med Econ. 2024. PMID: 39016841 Free article.

10

Budget impact analysis of the novel PD-1 inhibitor toripalimab versus pembrolizumab in recurrent or metastatic nasopharyngeal carcinoma.

Abraham I, Calamia M, Alkhatib N, Pondel M, MacDonald K. Abraham I, et al. Among authors: pondel m. J Med Econ. 2024;27(sup3):9-23. doi: 10.1080/13696998.2024.2379055. Epub 2024 Aug 18. J Med Econ. 2024. PMID: 39016811 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results